CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-09-04
DOI
10.3389/fonc.2021.710286
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs
- (2020) Maren Pein et al. Nature Communications
- Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer
- (2020) Li Yu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The UCSC Genome Browser database: 2021 update
- (2020) Jairo Navarro Gonzalez et al. NUCLEIC ACIDS RESEARCH
- M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
- (2020) Rui Zhao et al. OncoImmunology
- Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
- (2019) Melvyn T. Chow et al. IMMUNITY
- Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression
- (2019) Xiaojie Bian et al. Molecular Cancer
- Current Landscape of Immunotherapy in Breast Cancer
- (2019) Sylvia Adams et al. JAMA Oncology
- Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
- (2019) Denarda Dangaj et al. CANCER CELL
- CXCR3-CXCL9: It’s All in the Tumor
- (2019) Etienne Humblin et al. IMMUNITY
- The role of CXCL13 and CXCL9 in early breast cancer
- (2019) Evangelia Razis et al. Clinical Breast Cancer
- Role of CXCR3 signaling in response to anti-PD-1 therapy
- (2019) Xiao Han et al. EBioMedicine
- CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer
- (2019) Hua Zhang et al. CANCER CELL
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
- (2018) Ryuma Tokunaga et al. CANCER TREATMENT REVIEWS
- Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells
- (2018) Sonja Lieber et al. OncoImmunology
- Prognostic values of the inhibitor of DNA‑binding family members in breast cancer
- (2018) Xiao‑Ling Zhou et al. ONCOLOGY REPORTS
- Notch3 inhibits epithelial–mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression
- (2018) Hao-Yu Lin et al. Oncogenesis
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Inhibitor Therapy in Breast Cancer
- (2018) Cesar A. Santa-Maria et al. Journal of the National Comprehensive Cancer Network
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- Notch3 Maintains Luminal Phenotype and Suppresses Tumorigenesis and Metastasis of Breast Cancer via Trans-Activating Estrogen Receptor-α
- (2017) Xiao-Wei Dou et al. Theranostics
- UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
- (2017) Darshan S. Chandrashekar et al. NEOPLASIA
- Interleukin-30 Promotes Breast Cancer Growth and Progression
- (2016) Irma Airoldi et al. CANCER RESEARCH
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints
- (2015) M. E. Mikucki et al. Nature Communications
- HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers
- (2013) Mary L. Disis et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response
- (2013) Lára Hannesdóttir et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
- (2012) Leisha A Emens Expert Review of Anticancer Therapy
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab
- (2011) Stefan Glück et al. BREAST CANCER RESEARCH AND TREATMENT
- bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer
- (2011) Pascal Jézéquel et al. BREAST CANCER RESEARCH AND TREATMENT
- GOBO: Gene Expression-Based Outcome for Breast Cancer Online
- (2011) Markus Ringnér et al. PLoS One
- Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening
- (2010) E Ruiz-Garcia et al. BRITISH JOURNAL OF CANCER
- Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity - a tale of conflict and conundrum
- (2010) M. Müller et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism
- (2009) B Cambien et al. BRITISH JOURNAL OF CANCER
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- The Human Protein Atlas-a tool for pathology
- (2008) F Pontén et al. JOURNAL OF PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More